Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Drug Profile

Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Alternative Names: Hepatitis B vaccine - ISA Pharmaceuticals; HPV SLP®-AMPLIVANT™ vaccine; HPV16-peptides-AMPLIVANT-vaccine; ISA 203; ISA-204; MyISA®; Peptide vaccines - ISA Pharmaceuticals; PRAME vaccine; SLP-AMPLIVANT-conjugate-head-and-neck-cancer-vaccine; SLP® vaccines; SLP®-AMPLIVANT™ conjugate vaccines; SLP®-AMPLIVANT™ melanoma vaccine

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Hepatitis B vaccines; Immunotherapies; Peptide vaccines; Tuberculosis vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Hepatitis B; Viral infections
  • No development reported Tuberculosis

Most Recent Events

  • 08 Sep 2016 Preclinical trials in Hepatitis B in Netherlands (unspecified route) (ISA Pharmaceuticals pipeline, September 2016)
  • 24 Mar 2015 ISA Pharmaceuticals receives a European patent (EP 2 155 240) for the intradermal administration of synthetic long peptides based on HPV oncogenes
  • 15 May 2014 No development reported for Tuberculosis in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top